Introduction
Colorectal cancer (CRC) is the third most common malignancy in adults worldwide, with more than 6,000 million deaths each year. 1 Currently, the American Joint Committee on Cancer (AJCC) TNM staging system remains the strongest prognostic marker. However, growing evidence revealed that due to the considerable heterogeneity in CRC clinical presentation and prognosis, CRC should be subdivided into different prognostic groups by additional prognostic or predictive factors such as molecular biomarkers that reflect the development pathways of CRC. [2] [3] [4] [5] In the past cascades, the researchers have investigated a series of biomarkers and pathways including microsatellite instability (MSI) and mutation in B-type Raf kinase (BRAF), which are used as significant prognostic factors in intrinsic CRC subtypes. [6] [7] [8] [9] MSI, the molecular fingerprint of the deficient DNA mismatch repair (MMR) system, is caused by a lack of or alteration in MMR genes, which causes the accumulation of insertion and/or deletion in the microsatellite DNA domain. 10, 11 MSI, ie, deficient MMR, results from inheritance of a germline mutation in one of the MMR genes (MLH1, MSH2, MSH6, and PMS2) or more commonly from epigenetic inactivation of MLH. 12, 13 MSI occurs in ~15% of cases in CRC and usually favorable for the clinical outcomes in CRC in contrast to microsatellite stable (MSS). [14] [15] [16] MSI can be evaluated by immunohistochemistry (IHC) analysis of MLH1, MSH2, MSH6, and PMS2 or by MSI testing.
BRAF, a member of the RAF family, is an essential intermediary in the RAS/RAF/mitogen-activated protein kinase (MAPK) signaling cascade and is commonly activated by its mutations. [17] [18] [19] BRAF V600E missense mutation is a valine (V) to glutamic acid (E) switch at codon 600 caused by the c.1799T>A transversion and accounts for 80% of BRAF mutations. 20 BRAF V600E mutation occurs in about 14% of CRC cases and more frequently in sporadic CRC with MSI. 21 However, in contrast to MSI, BRAF V600E mutation shows an independent negative prognostic association with survival in CRC. [22] [23] [24] [25] Recent findings indicate that the prognostic potential of MSI can override the negative prognostic potential of BRAFV600E. 7, 26 A number of studies have been performed to investigate the clinical utility of the combination of MSI status and BRAF mutation; however, the results are inconsistent and inconclusive and the sample size of the individual study is limited.
In the present study, we performed a meta-analysis for the first time to explore the prognostic role of the combination of MSI status and BRAF V600E mutation in CRC.
Materials and methods

Publication search
A systematic search was performed to obtain the published articles that report the prognostic effects of the combination of MSI status and BRAF mutation in CRC in three English databases (PubMed, EMBASE, and Web of Science) up to December 30, 2017 . The following terms were used as keywords in searching: "colorectal OR colon OR rectal", "cancer OR tumor OR carcinoma", "mismatch repair OR MMR OR microsatellite instability OR MSI", "B-type Raf kinase OR BRAF", and "prognosis OR survival OR overall survival OR recurrence-free survival OR RFS OR progression-free survival OR PFS". The retrieved articles were screened and selected by two independent investigators according to the inclusion and exclusion criteria. We also screened the review articles and the references of selected articles to identify additional eligible studies. In addition, the public databases, TCGA and NCBI GEO, were utilized to search for eligible studies.
inclusion and exclusion criteria
Inclusion criteria were as follows: 1) the histologic type of the tumors was limited to CRC; 2) the associations of the combination of MSI and BRAF mutation with RFS, PFS, and/or overall survival (OS) in CRC were evaluated; 3) the sample size of the study was more than 200, and when one study reported only MSI CRCs, the sample size should be more than 50; 4) full peer-reviewed articles that have been published as full texts; and 5) only the studies published in English. Exclusion criteria were as follows: 1) study with insufficient or duplicate data and 2) abstracts, letters, or review articles.
Data extraction
The following characteristics of eligible studies and related data were collected by two independent authors carefully: name of the first author; year of publication; country of origin; patient sex and age; cancer type; TNM stage; frequency of MSI/BRAFmut, MSI/BRAFwt, MSS/BRAFmut, and MSS/ BRAFwt; sample size; and HRs with their 95% CI that reflect the associations of the combination of MSI and BRAF with RFS, PFS, or OS. If the study reports both the data calculated by univariate and multivariate analyses, only the adjusted HRs and 95% CIs in multivariate analysis were selected. If one study only reported a Kaplan-Meier plot curve, HR and its 95% CI were evaluated according to the previous reports. 27 Inconsistency was solved by discussion among the authors.
Quality score assessment
The Newcastle Ottawa Scale (NOS) was used to evaluate the methodological quality of each eligible article in our metaanalysis according to the following three aspects: selection, comparability, and exposure, with scores ranging from 0 to 9. The study was defined as high quality if the NOS score was more than 7. 
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, otherwise, the pooled HRs were calculated by random-effects model. 28 The stabilities of the pooled HRs were evaluated by sensitivity analysis by omitting each study in every turn. At the same time, subgroup analyses were performed according to the cancer type (colon cancer [CC] and mixed types, which included both CC and rectal cancer, and the results of CC and rectal cancer could not be separated), tumor stage (TNM I-III and IV), therapeutic strategy (surgery with or without adjuvant chemotherapy and first-line chemotherapy), sample size (<500, 500-1000, and >1,000 cases), and methods for obtaining HR (M, U, and KM, which were obtained from multivariate analysis, univariate analysis, and Kaplan-Meier plot curves, respectively). Potential publication bias was explored by Begg's funnel plots and Egger's test. 29, 30 Influence of a covariate on the association of one factor with OS in CRC was analyzed by meta-analysis regression and test of interaction.
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Results
study characteristics
The literature selection process is shown in Figure 1 . A total of 3,493 documents were initially identified from three English databases. After excluding those duplicated papers, reviews or meeting abstracts, and irrelevant papers, 44 articles were further evaluated. Subsequently, 21 articles were excluded according to the inclusion and exclusion criteria, of which three articles did not report RFS, PFS, or OS outcomes related to the MSI/BRAF mutation status, [32] [33] [34] nine had overlapped data with other studies, [35] [36] [37] [38] [39] [40] [41] [42] [43] five articles included small sample size, [44] [45] [46] [47] [48] six reported no sufficient data, [49] [50] [51] [52] [53] [54] and HR in one article could not be calculated correctly from the Kaplan-Meier plot curve. 55 Finally, 23 eligible articles containing 26 cohort studies were included in the present meta-analysis. 7 
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Yang et al were also included in subgroup analysis stratified by cancer type and stage. 38, 39, 42 Furthermore, public available data sets from online databases, TCGA and NCBI GEO, were also screened according to the criteria, and only a data set, GSE39582, was selected. 76 In total, 27 independent cohort studies containing 24,067 cases were included. Quality assessment was performed, and all the studies achieved a high NOS score (≥7, data not shown). The characteristics of the included studies are summarized in Table 1 .
associations of Msi/BRAF mutation status with RFs and Os in CC in gse39582
There were 465 CC cases in GSE39582. The average age of the patients was 67.2 years. Two hundred fifty-seven cases were males and 208 were females. Two hundred sixty-five patients received adjuvant chemotherapy after resection. Kaplan-Meier plot curve and Cox proportional hazards models were performed to clarify the associations of the MSI/BRAF mutation status with RFS and OS ( Figure 2 and Figure 3D and Figure 4 and Table 3 ). In contrast, there was no significant difference in PFS in other comparisons. Subgroup analysis was not performed due to the limited included studies.
Os
Next, the prognostic value of the combination of MSI and BRAF mutation in OS in CRC was analyzed. Overall, BRAF mutation was a poor factor for OS in both MSS (MSS/ BRAFmut vs MSS/BRAFwt: N=25, HR = 2.018, 95% CI = 1.706-2.388, P=2.220E-16; Figure 5A and Table 4 ) and MSI patients (MSI/BRAFmut vs MSI/BRAFwt: N=22, HR = 1.470, 95% CI = 1.243-1.740, P=7.122E-06; Figure 5B ). MSI was a favorable factor for OS in BRAF-mutated patients (MSI/BRAFmut vs MSS/BRAFmut: N=16, HR = 0.741, 95% CI = 0.567-0.968, P=2.781E-02; Figure 5C ) but not in BRAF wild-type patients (MSI/BRAFwt vs MSS/BRAFwt: N=17, HR = 0.996, 95% CI = 0.801-1.240, P=9.761E-01; Figure 5D ). In addition, MSI decreased the negative prognostic potential of BRAF mutations to a non-significant Note: Bold, statistically significant. Abbreviations: aC, adjuvant chemotherapy; CC, colon cancer; M, hR was obtained from multivariate analysis; MiX, the studies included both CC and rectal cancer and results of which could not be separated; KM, hR was obtained indirectly from Kaplan-Meier plot curves; Msi, microsatellite instability; Msimut, microsatellite instability and BRAF mutation; Msiwt, microsatellite instability and BRAF wild type; Mssmut, microsatellite stable and BRAF mutation; Msswt, microsatellite stable and BRAF wild type; RFs, recurrence free survival; S, surgery; U, HR was obtained from univariate analysis; R, random-effects model; F, fixed-effects model. 
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Yang et al analyzed the influence of prevalence of proximal/right-sided cancer on the associations in comparisons of different MSI/ BRAF mutation subtypes by meta-analysis regression and no significant result was found (Table S1) .
heterogeneity, publication bias, and sensitivity analysis
For RFS, no heterogeneity was found by all comparisons (Table 3) For MSI/BRAFmut vs MSS/BRAFmut, heterogeneity reduced in subgroups of stage IV, surgery plus adjuvant chemotherapy, chemotherapy, and 500-1000 cases. Potential publication bias was first evaluated by Begg's funnel plots. Symmetrical funnel plots were obtained in all analyses ( Figure 6 ). The Egger's test was also performed to provide the statistical evidence of publication bias, and the results did not show publication bias in all the pooling analyses (Tables 3 and 4) . Finally, the sensitivity analysis was performed to examine the influence set by the individual study on the pooled HRs by deleting each study once. All the results were almost same with the overall results in all comparisons ( Figure 7 ).
interaction of Msi and BRAF mutation
In the included studies, the prevalence of BRAF mutation in MSI cases was much higher than that in MSS cases (45.5% vs 7.1%, pooled OR = 11.247, 95% CI = 8.734-14.482, P=0.000E+00), suggesting a significant association of MSI with BRAF mutation in CRC, which promoted us to investigate the interaction of MSI and BRAF mutation when evaluating the associations of MSI/BRAF mutation status with OS in CRC. Meta-analysis regression suggested that MSI did not influence the association of BRAF mutation with OS in CRC (coefficient = −0.041, Z=−0.290, P=7.718E-01; Table 5 ). Test of interaction was performed according to the method suggested in the previous report, 31 and no interaction of MSI with BRAF mutation was observed.
Discussion
CRC is a heterogeneous disease and presents significant difference in clinical presentation, prognosis, and treatment response, even at the same pathological stage. Additional molecular biomarkers such as MSI and BRAF mutation have been mostly investigated to classify CRC into intrinsic subtypes and predict the therapy response and prognosis. [6] [7] [8] [9] However, due to the opposing effects between MSI and BRAF mutation in general, whether the concomitant evaluation of both MSI and BRAF status provides an additive or subtractive effect on patient outcome is not conclusive and consistent.
The previous studies suggested that the frequencies of MSI and BRAF mutation in CRC were ~15% and 14%, respectively. 14, 15, 77 In the present study, of the 24,067 cases, 11.9% cases were with MSI phenotype and 11.6% cases with BRAF mutation, a little smaller than that in the previously reported study. 21 The prevalence of BRAF mutation in MSI cases was much higher than that in MSS cases. However, the frequency of MSI or BRAF mutation in individual studies ranged drastically (MSI: 1.5%-22.6%; BRAF mutation: 3.0%-24.3%), which might be due to the diversity of the included CRC patients and different detection methods for the molecular biomarkers.
Currently, several meta-analyses studies have been performed to investigate the prognostic value of MSI or BRAF mutation in CRC. Gkekas et al 78 have pooled 19 studies containing 5,998 cases and found no significant association of MSI with OS (HR = 0.73, 95% CI = 0.33-1.65) and disease-free survival (DFS; HR = 0.60, 95% CI = 0.27-1.32) in stage II CC. In 2012, Safaee Ardekani et al 79 combined 26 studies including 11,773 patients and found that BRAF mutation was significantly associated with OS in CRC (HR = 2.25, 95% CI = 1.82-2.83). Multiple meta-analyses were performed in mCRC to explore the associations of BRAF mutation with prognosis and achieved consistent results that BRAF mutation was significantly associated with shorter PFS and OS. [80] [81] [82] [83] [84] In stage II-III CRC treated with surgery and adjuvant therapy, BRAF mutation was also found to be associated with shorter OS and DFS. 85 However, there was no meta-analysis study summarizing the prognosis of the CRC patients with different subtypes defined by MSI and 
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Prognostic value of MSI/BRAF mutation status in CRC Abbreviations: Msi, microsatellite instability; Msimut, microsatellite instability and BRAF mutation; Msiwt, microsatellite instability and BRAF wild type; Mssmut, microsatellite stable and BRAF mutation; Msswt, microsatellite stable and BRAF wild type; Os, overall survival. 
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Prognostic value of MSI/BRAF mutation status in CRC BRAFwt, and MSI/BRAFmut. In the present study, our results suggested that BRAF mutation was associated with shorter OS in both MSS CRC patients and MSI CRC patients overall and in all subgroups stratified by cancer type, tumor stage, and treatment, which were similar with the prognostic value of BRAF mutation in entire CRC and mCRC. [79] [80] [81] [82] [83] [84] Similar to the previous results, we also found the poor prognostic effects of BRAF mutation in both MSS and MSI CRC treated with surgery and adjuvant therapy, and MSI did not change the poor effect of BRAF mutation. 85 Our results also revealed that MSI was not associated with OS in BRAFwt patents with CRC overall or in stage I-III CRC, similar to the study by Gkekas et al 78 performed in stage II CC regardless of BRAF mutation. In contrast, MSI was a favorable factor for OS in BRAF-mutated CRC patients. On the basis of the previous reports and our results, we speculated that the effect of BRAF mutation was bigger than that of MSI. To predict prognosis, CRC should be stratified by BRAF mutation first ( Figure 8A ). MSS/BRAFmut was a poor prognostic factor, while MSS/ BRAFwt and MSI/BRAFwt were comparable and favorable Table 4 ). In the subgroup of stage IV, unlike the subgroup of stage I-III, MSI showed poor effects on OS in BRAF wild-type patients ( Figure 8C and Table 4 ). This might be not consistent with the current knowledge that MSI status did not affect the prognosis in mCRC. Due to the limited included studies of mCRC, the results for MSI might be not stable. Thus, we screened the published literature reporting the prognostic value of MSI status in mCRC regardless of BRAF mutations. After pooling the crude HRs from 20 primary studies, we did not find significant associations of MSI with OS in CRC. However, when stratifying by the frequency of MSI, we found that MSI was a poor factor for OS in the subgroup with low frequency of MSI, while MSI was a favorable factor for OS in the subgroup with high frequency of MSI (data not shown).
We speculated that the prognostic value of MSI in mCRC was affected by the detected frequency of MSI. Although we pooled all the potential studies with big sample size and high methodological quality, some conclusions in the present studies should be treated carefully. First, although we performed subgroup analysis according to the cancer type, stage, and therapy, other tumor characteristics such as vascular invasion, tumor differentiation, and tumor budding in localized CRC and ECOG performance status and number of organs in mCRC were not analyzed due to the rare original data in the primary studies. Second, crude HRs were obtained by different methods, such as univariate and multivariate analyses and Kaplan-Meier plot curve, especially for HRs calculated from Kaplan-Meier plot curve, which might deviate from the "real" HRs derived from original data. All these differences might bring unreliability to the conclusions of the present meta-analysis. Thus, further well-designed studies with larger sample size and detailed clinical characteristics and treatments should be conducted to confirm the results and avoid potential biases.
In summary, we got a comprehensive result from the current meta-analysis that among the four subtypes according to MSI and BRAF mutation in CRC, MSS/BRAFmut was a poor prognostic factor, while MSS/BRAFwt and MSI/BRAFwt were comparable and favorable and MSI/BRAFmut was moderate in overall and stage I-III CRC. In stage IV CRC, especially those with BRAF wt, MSI played an unfavorable role in prognosis. The results suggested that the combination of MSI and BRAF could predict prognosis in CRC and facilitated the planning of individualized treatment strategies, thereby improving the prognosis in the CRC patients with more aggressive genetic background.
